Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 10/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340318 | 0.92 | EPHX2 (0.43) | SLC2A2GRM5SMOEPHX2NPSR1 | |
| SCHEMBL339823 | 0.90 | TSHR (0.42) | GRM5NPSR1HTTSLC6A15ALDH1A1 | |
| SCHEMBL339494 | 0.88 | SLC2A1 (0.43) | SLC2A2SMONPSR1MAPTSMN1; SMN2 | |
| SCHEMBL339604 | 0.87 | AKT1 (0.44) | SMONPSR1ALDH1A1MAPT | |
| SCHEMBL338824 | 0.86 | DPP4 (0.37) | GRM5SLC6A15 | |
| SCHEMBL338966 | 0.85 | ALDH1A1 (0.46) | SLC2A2EPHX2NPSR1HTTKDM4E | |
| SCHEMBL1911465 | 0.83 | IDE (0.46) | SLC2A2EPHX2NPSR1HTTKDM4E | |
| SCHEMBL868597 | 0.83 | MAPK1 (0.46) | SLC2A2NPSR1HTTKDM4EALDH1A1 | |
| SCHEMBL338785 | 0.83 | DPP4 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL338907 | 0.83 | DPP4 (0.38) | SLC2A2GRM5RETSLC6A15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | SLC2A2 27/4885GRM5 2618/4885SMO 1568/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | SLC2A2 27/4885GRM5 2618/4885SMO 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.